Strategic partnerships Sanfer has recent and notable expansion activity through acquisitions and collaborations, including acquiring Vitalis and a distribution partnership with Hanmi Pharma for GLP-1 therapies. This indicates a growth trajectory and potential for co-marketing, exclusive distribution, and joint penetration into chronic disease segments.

Chronic disease focus The portfolio includes therapies across multiple ATC classes with emphasis on systems related to metabolic, cardiovascular, endocrinology, and anti-diabetic treatments, plus GLP-1 therapy. This creates openings for selling hospital and specialty channels focused on diabetes, obesity, and chronic disease management.

International footprint Sanfer operates through a broad regional network in Latin America and beyond, with subsidiaries in multiple countries. This regional scale supports cross-border supply, shared manufacturing or contract manufacturing opportunities, and regional tenders or partnerships with public health programs.

Financial stability With a substantial funding backdrop and revenue range in the hundreds of millions, plus significant strategic investment in the past, Sanfer presents a solid financial profile that can support co-development deals, tender participation, and larger deal opportunities with health authorities and distributors.

Animal and human health synergies Sanfer Health Animal assets and family of brands indicate a diversified health approach. Opportunities exist to cross-sell human and animal health products, leverage existing distribution networks for veterinary markets, and explore bundled or segment-specific solutions for clinics serving both human and animal health customers.